BENICIA, Calif., Oct. 22 /PRNewswire/ -- AcroMetrix, the leading provider of quality control standards for clinical diagnostic and blood testing laboratories, announced that they have enhanced their OptiQuant HIV-1 Quantification Panel to be the first to utilize an EDTA-based normal human plasma matrix. This product is for Research Use Only, not for use in diagnostic procedures.
This new matrix, called OptiMatrix, allows the OptiQuant HIV-1 panel to most closely mimic a patient sample. The commutability of the OptiQuant HIV panel ensures accurate comparison and compatibility between a wide variety of testing platforms globally. As a further improvement, AcroMetrix panel members are the first to be directly traceable to International Units per milliliter (IU/mL) to facilitate global quality through ISO standards.
"The OptiQuant HIV-1 Quantification Panel represents our commitment to standardization in diagnostics," said Michael J. Eck, President and CEO. "The new OptiQuant panel is the first HIV validation panel available to be traceable to the WHO standard, in a truly commutable matrix."
This new OptiQuant HIV Panel fully complies with the ISO 17511:2003 (In vitro diagnostic medical devices -- Measurement of quantities in biological samples -- Metrological traceability of values assigned to calibrators and control materials) standard. Through the ISO 17511 standard, AcroMetrix aims to facilitate a uniform global quality control network by producing consistent and traceable universal standards.
"Our goal is to standardize diagnostic testing so that a patient can receive a truly comparable test result regardless of the doctor or laboratory they choose to visit," said Mr. Eck, "The new OptiQuant HIV panel is a step in that direction for HIV viral load testing."
AcroMetrix, with facilities in Benicia, California and Alkmaar, the
Netherlands, provides a comprehensive line of molecular and serological
Copyright©2007 PR Newswire.
All rights reserved